Skip to content
OpenCapital
Get started

Integra LifeSciences IART Cash & Equivalents

Cash & Equivalents at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$1.02B+49.0%
Stryker logo
StrykerSYK
$2.88B+24.1%
Axogen logo
AxogenAXGN
$84.65M+251%
Globus Medical logo
Globus MedicalGMED
$560.95M+21.6%
AbbVie logo
AbbVieABBV
$9.39B+81.5%
Medtronic logo
MedtronicMDT
$1.95B-12.1%

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B-56.8%
Enterprise value$3.12B-26.7%
P/S0.8×-1.1×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%—
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%—
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's cash & equivalents?
Integra LifeSciences (IART) reported cash & equivalents of $236.81M in Q1 2026.
How has Integra LifeSciences's cash & equivalents changed year-over-year?
Integra LifeSciences's cash & equivalents decreased by 1.0% year-over-year, from $239.1M to $236.81M.
What is the long-term trend for Integra LifeSciences's cash & equivalents?
Over 5 years (2020 to 2025), Integra LifeSciences's cash & equivalents has grown at a -12.9% compound annual growth rate (CAGR), from $470.17M to $235.05M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.